Drugs
Researchers from Hallym University in South Korea conducted a phase I study to evaluate the maximum tolerated dose (MTD), recommended dose (RD), and activity of a combined chemotherapy regimen of docetaxel, oxaliplatin, and S-1 in patients with metastatic gastric cancer. The study aimed to determine the optimal doses of each
Drugs
Researchers at Tohoku University in Sendai, Japan, have discovered that the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), significantly enhances the efficacy of cisplatin (CDDP) in inducing apoptosis in oral squamous cell carcinoma (OSCC) cells. The study, published in Cancer Chemotherapy and Pharmacology, found that SAHA potently induces apoptosis in
Drugs
Scientists at the University of Saskatchewan in Saskatoon, Canada have published a report in the Journal of Cardiovascular Pharmacology and Therapeutics on the effects of vitamin E on hypercholesterolemic atherosclerosis. The study involved four groups of rabbits fed different diets to observe the effects of vitamin E on atherosclerosis. The
Drugs
Researchers in Nanjing, People's Republic of China, have developed a conjugate preparation of an antibody-superantigen conjugate that shows promising effects in treating bladder cancer. The conjugate, made by linking an antibody fragment to a superantigen, targets bladder carcinoma cells in vitro while minimizing cytotoxicity to non-malignant cells. This
Drugs
A study conducted in Villejuif, France, investigated the efficacy and tolerability of motesanib, a selective inhibitor of vascular endothelial growth factor receptors, in patients with advanced medullary thyroid cancer (MTC). The study enrolled 91 patients who received motesanib 125 mg/d orally for up to 48 weeks. The primary end
Drugs
Chronic myeloid leukemia (CML) treatment has evolved significantly with the introduction of imatinib, a drug that induces durable responses and prolonged progression-free survival. However, plasma exposure to imatinib can vary widely among patients, and blood-level testing may be necessary to make informed clinical decisions. Researchers at the University of Texas,
Drugs
Doxorubicin (DOX) is a widely prescribed chemotherapeutic agent known to induce cardiomyocyte apoptosis. Researchers from Coimbra, Portugal, led by V.A. Sardo, discovered that DOX-induced mitochondrial dysfunction is a consequence of nuclear p53 activation rather than a direct effect of the drug on mitochondria. The study, published in Cancer Chemotherapy
Drugs
Researchers at the University of Manchester in the United Kingdom have made significant findings in the early detection and prognosis of small cell lung cancer (SCLC) by analyzing circulating tumor cells (CTCs) and serological cell death biomarkers. The study, published in the American Journal of Pathology, evaluated the expression and
Drugs
Breast cancer patients are often prescribed tamoxifen, a selective estrogen receptor modulator, for treatment and prevention of estrogen-receptor-positive breast cancer. However, studies have shown that over half of these patients discontinue treatment before the recommended 5 years. Researchers from the University of Michigan have found a strong correlation between CYP2D6
Drugs
Recent research from Taichung, Taiwan, has shed light on the complex effects of rapamycin, an immunosuppressant drug, on metabolic health. The study, conducted by G.R. Chang and colleagues from the National Chung-Hsing University, Department of Veterinary Medicine, investigated the effects of rapamycin on obese animal models. The findings suggest
Drugs
Researchers in the United States have discovered that MLH1 deficiency significantly enhances tumor cell sensitivity to ganciclovir, a crucial finding in the field of cancer gene therapy. By employing HSV-TK and ganciclovir, scientists have observed a unique pattern of delayed cytotoxicity in S-phase cells. The study suggests that MLH1, an
Drugs
Investigators in the United States conducted preclinical biodistribution studies with INGN 007, an oncolytic adenovirus vector, in Syrian hamsters and mice to support an early-stage clinical trial. The study examined vector dissemination and pharmacokinetics following intravenous administration in nine tissues and blood at five time points spanning one year. The
